MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/acn3.50952

Медицинская библиотека · Annals of clinical and translational neurology · 2019

Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1.

Payne Jonathan M, Hearps Stephen J C, Walsh Karin S, Paltin Iris, Barton Belinda, Ullrich Nicole J, Haebich Kristina M, Coghill David, Gioia Gerard A, Cantor Alan, Cutter Gary, Tonsgard James H, Viskochil David, Rey-Casserly Celiane, Schorry Elizabeth K, Ackerson Joseph D, Klesse Laura, Fisher Michael J, Gutmann David H, Rosser Tena, Packer Roger J, Korf Bruce, Acosta Maria T, North Kathryn N, NF Clinical Trials Consortium

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

Rapid developments in understanding the molecular mechanisms underlying cognitive deficits in neurodevelopmental disorders have increased expectations for targeted, mechanism-based treatments. However, translation from preclinical models to human clinical trials has proven challenging. Poor reproducibility of cognitive endpoints may provide one explanation for this finding. We examined the suitability of cognitive outcomes for clinical trials in children with neurofibromatosis type 1 (NF1) by examining test-retest reliability of the measures and the application of data reduction techniques to improve reproducibility.

METHODS

Data were analyzed from the STARS clinical trial (n = 146), a multi-center double-blind placebo-controlled phase II trial of lovastatin, conducted by the NF Clinical Trials Consortium. Intra-class correlation coefficients were generated between pre- and post-performances (16-week interval) on neuropsychological endpoints in the placebo group to determine test-retest reliabilities. Confirmatory factor analysis was used to reduce data into cognitive domains and account for measurement error.

RESULTS

Test-retest reliabilities were highly variable, with most endpoints demonstrating unacceptably low reproducibility. Data reduction confirmed four distinct neuropsychological domains: executive functioning/attention, visuospatial ability, memory, and behavior. Test-retest reliabilities of latent factors improved to acceptable levels for clinical trials. Applicability and utility of our model was demonstrated by homogeneous effect sizes in the reanalyzed efficacy data.

INTERPRETATION: These data demonstrate that single observed endpoints are not appropriate to determine efficacy, partly accounting for the poor test-retest reliability of cognitive outcomes in clinical trials in neurodevelopmental disorders. Recommendations to improve reproducibility are outlined to guide future trial design.

Для цитирования: Payne Jonathan M, Hearps Stephen J C, Walsh Karin S, Paltin Iris, Barton Belinda, Ullrich Nicole J, Haebich Kristina M, Coghill David, Gioia Gerard A, Cantor Alan, Cutter Gary, Tonsgard James H, Viskochil David, Rey-Casserly Celiane, Schorry Elizabeth K, Ackerson Joseph D, Klesse Laura, Fisher Michael J, Gutmann David H, Rosser Tena, Packer Roger J, Korf Bruce, Acosta Maria T, North Kathryn N, NF Clinical Trials Consortium. Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1.. Annals of clinical and translational neurology. 2019. DOI: 10.1002/acn3.50952.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.